Avsar.

Healthcare · Pharmaceuticals

Bliss GVS Pharma Ltd (BLISSGVS)

₹647.50

Mkt cap
₹6,888 Cr
P/E ratio
42.40
P/B
5.35
Div yield
0.23%
ROE
11.80%
ROCE
16.90%
EPS (TTM)
₹15.27
Book value
₹121
52W range
118–740
Sector
Healthcare

Price history

Previous close

Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.

NSE BLISSGVSBSE 506197
Health check
Mixed
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−12.49% from high
₹648
₹118+448.73% from low₹740
Current
₹647.50
Prev close
₹680.90
Day
−4.91%
Price performance
1D
−4.30%
1W
+4.54%
1M
−8.33%
3M
+43.17%
6M
+143.74%
1Y
+320.64%
YTD
+297.68%

Financials

Revenue, profit & margin
P/E ratio
42.4×
BLISSGVS is 23% above the sector median of 34.4×
BLISSGVS42.4×
Sector median34.4×
 Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Trend
Sales212201198184218210198207244218257286313
Expenses158157170149176181177166201183213209233
Operating Profit54442834413021414335447681
OPM %26%22%14%19%19%14%11%20%18%16%17%27%26%
Other Income135-244515123581611108
Interest1222412531213
Depreciation677778888891010
Profit before tax5940-430363623634141457575
Tax %27%27%24%26%28%29%29%30%30%39%18%32%29%
Net Profit4329-522262617442925375153
EPS in Rs4.052.64-0.871.972.312.261.474.082.582.203.364.724.91
Raw PDF

Earnings

Results dates & reactions
No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +0.35% · closed higher next day 1 of last 1
 Q1FY27†Q2FY27
Broadcast12 Aug '26◦29 Oct '26◦
Earnings day+4.99%−4.30%
+1 day+6.07%—
+5 days+18.51%—
+15 days+30.60%—
+30 days+43.95%—
FilingPDFXBRL

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Results analysis

Shareholding

as of Sep 2026
50.07%Promoter
Promoters50.07%15.06
FIIs5.03%3.04
DIIs9.62%0.16
Public35.29%12.16
Ownership trend

Peers

8 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Sun Pharma.Inds.₹1,777.7034.664,26,5300.90%1,995−10.53%16,199+11.88%20.53%
Divi's Lab.₹9,780.0087.142,59,6280.31%902+65.50%3,080+27.80%21.97%
Torrent Pharma.₹4,613.4080.831,75,4790.82%534−10.03%4,979+50.79%15.19%
Laurus Labs₹2,405.5097.001,29,9720.08%436+126.43%2,206+33.44%17.76%
Zydus Lifesci.₹1,245.5025.521,24,2390.08%990−35.09%8,017+21.96%21.14%
Dr Reddy's Labs₹1,352.0040.301,12,8490.59%913−31.35%8,698−1.48%13.04%
Cipla₹1,378.9035.871,11,3970.94%852−35.05%7,404−2.44%15.49%
Bliss GVS Pharma₹647.5042.366,8880.23%53+91.74%313+28.22%16.93%
Median: 158 Co.₹426.3834.391,9210.08%14+22.08%175+18.92%15.12%

Filings

Annual reports15
Annual Report 2026Annual Report 2025Annual Report 2024Annual Report 2023Annual Report 2022Annual Report 2021Annual Report 2020Annual Report 2019Annual Report 2018Annual Report 2017Annual Report 2016Annual Report 2015Annual Report 2014Annual Report 2013Annual Report 2012
Concall transcripts7
PPTAug 2019PPTMay 2019PPTFeb 2019PPTNov 2018PPTAug 2018PPTMay 2018PPTJan 2018
Credit ratings6
Rating update 5 JuncrisilRating update 2 JunicraRating update 11 MaycrisilRating update 8 ApricraRating update 2 Sep 2025crisilRating update 26 Jun 2024infomerics
Announcements5
Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Option Plan 2019 29 Oct - Bliss GVS Pharma granted 2,95,000 stock options under ESOP 2019 on October 29, 2026.Board Meeting Outcome for Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2026 29 Oct - Board approved unaudited standalone and consolidated results for quarter and half year ended September 30, 2026.Board Meeting Outcome for Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2026 29 Oct - Board approved unaudited standalone and consolidated results for quarter and half year ended September 30, 2026.Unaudited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2026 29 OctAnnouncement under Regulation 30 (LODR)-Newspaper Publication 29 Oct - The Newspaper Publication regarding the Postal Ballot Notice dated October 01, 2026.